source
- Life insurers deem active-surveillance prostate cancer 'untreated' and deny term coverage, says patientHoward Wolinsky, a medical journalist, recounts that after his term life policy expired, eight insurers rejected his application because they considered his prostate cancer, managed by active surve…
- AstraZeneca launches $1 billion R&D hub in Boston’s Kendall SquareAstraZeneca opened a new research and development site in Kendall Square, Boston, marking a $1 billion investment in the U.S. biotech corridor. The Boston location underscores the company’s commit…